What is Evommune 's revenue?

Evommune (EVMN) generated $6.7M in revenue over the trailing twelve months.

Is Evommune profitable?

Evommune is not currently profitable: it reported a net loss of $6.0M over the trailing twelve months, a -90.1% net margin.

What are Evommune 's profit margins?

Gross margin is 53.7% and operating margin is -30.7%, with a -90.1% net margin.

What is Evommune 's earnings per share?

Evommune 's diluted EPS over the trailing twelve months is $-0.32.

Where does Evommune 's income statement data come from?

Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Evommune EVMN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25
Total revenue	$6.61M—
Total cost of revenue	$3.13M—
Gross profit	$3.48M—
Gross margin	52.7%—
Selling and marketing	$632.41K—
General and administrative	$4.25M—
Compensation and benefits	——
Depreciation and amortization	——
Provision for credit losses	——
Other operating expenses	$4.88M—
Total operating expenses	$4.88M—
Operating income	-$1.4M—
Operating margin	-21.2%—
Interest expense	$402.4K—
Income from equity method investments	——
Gain (loss) on extinguishment of debt	——
Net investment gains (losses)	——
Net income	——
Diluted earnings per share	——
Basic earnings per share	——
Weighted-average shares, diluted	99.2M—
Weighted-average shares, basic	——
Loss On Issuance Of Preferred Stock Derivative Liability	$5.29M—
Accounts Payable And Accrued Liabilities	$78.87K—
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition	——
Issuance of warrants to purchase common stock	——
Aggregate Assigned Value	——
Allowance For Inventory Obsolescence	——
Amortization of capitalized software and acquired intangible assets	——
Asset Acquisition Consideration Transferred	——
Base Monthly Rent	——
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect	——
Change In Additional Paid In Capital	$2.63M—
Common Stock Convertible Conversion Percentage Decrease	——
Common Stock Convertible Conversion Percentage Increase	——
Common Stock Issued For Convertible Note Payable And Accrued Interest	$122.33K—
Conversion Of Common Stock Percentage Closing Price	——
Declaration Of Preferred Stock Dividend Recorded As Increase In Accrued Liabilities	——
Deferred Offering Cost	-$2.31M—
Depreciation	——
Derecognition Of Derivative Liabilities Upon Extinguishment Of Series Aamp B Preferred Shares	——
Derecognition Upon Exchangein Shares	——
Derecognition Upon Share Buybacks	-$1.38M—
Derivative, Gain (Loss) on Derivative, Net	$7.36M—
Derivative Liability	$13.29M—
Derivative Liability Upon Conversions Of Preferred Shares	-$1.25M—
Dividends, Preferred Stock, Stock	$78.87K—
Embedded derivatives gain (loss)	——
Extinguishment Of Series Aamp B Preferred Shares	——
Fair Value Adjustment Decreasing Derivative Liability	$7.36M—
Financing Expense On Warrant Issuance	——
Acquired intangibles	——
Gain (loss) on sale of derivatives	-$7.36M—
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions	——
Accounts payable and other current liabilities	——
Increase (Decrease) in Accounts Receivable	——
Increase (Decrease) in Inventories	——
Short- and long-term operating lease liabilities	——
Increase (decrease) in other current liabilities	——
Increase (Decrease) in Prepaid Expense and Other Assets	——
Increase In Other Income Expense	——
Increase Other Income Of Reimbursement	$419.95K—
Initial Recognition Of Derivative Liability Upon Issuance	$13.29M—
Debt	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	——
Issuance Of Common Stock For Convertible Debenture	$122.33K—
Issuance Of Series C Preferred Shares	——
Issuance Of Shares For Note Extension	$80.5K—
Line of Credit Facility, Interest Rate During Period	——
Line Of Credit Facility Periodic Payment Principal	$3.38K—
Mandatory Repayment Percentage Of Net Proceeds	——
Monitoring Fee	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	——
Net Of Commissions Received	——
Number of operating segments	——
Obligation Payment	——
Operating Lease Payments	——
Operating lease right-of-use assets amortization expense	——
Membership and other income	——
Other income, net (Note 6)	——
Ownership Limit Percentage Of Outstanding Common Stock Upon Conversion	——
Payments For Payable For Acquisition	——
Rent expense	——
Payments for Repurchase of Preferred Stock and Preference Stock	$180.33K—
Payments Of Stock Issuance Costs	——
Percentage Of Alternative Conversion Price	——
Percentage Of Beneficial Ownership Limitation	——
Percentage Of Daily Trading Volume	——
Percentage Of Default Interest Rate	——
Percentage Of Default Premium	——
Percentage Of Fixed Conversion Price	——
Percentage Of Maximum Beneficial Ownership Limitation	——
Percentage Of Net Sales	——
Percentage Of Outstanding Principal Amount	——
Percentage Of Remaining Stated Value Of The Exchanged Share	——
Proceeds from issuance of preferred stock	$8M—
Proceeds From Issuance Of Private Placement	——
Proceeds from revolver	——
Net additions (releases) charged to costs and expenses	——
Reclass Common Stock Issued For Legal Services To Deferred Offering Costsin Dollars	-$252K—
Recognition Of Derivative Liabilities Upon Issuance Of Series C Preferred Sharesamp Convertible Notes	——
Recognition Of Series C Convertible Notes	——
Repayment Of Liability Conditional Timing	——
Repayments of Debt	——
Repayments of Lines of Credit	——
Repayments of Long-Term Debt	——
Stock-based compensation	——
New issues (in shares)	——
Stock Issued During Period, Value, Conversion of Convertible Securities	——
Stock Issued During Period Value Conversion Of Preferred Stock	$1.25M—
Stock Issued During Period Value Deferred Offering Cost	$2.31M—
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	——
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	$543.07K—
Stock Issued During Period Value Warrants Exercises	——
Purchase price	$1.2M—
Change in fair value of interest rate swap	$7.36M—
Unrealized Loss On Issuance Of Preferred Stock	$5.29M—
Weighted Average Number Of Diluted Share Outstanding	——
Weighted Average Number Of Shares Dilutive Effect Of Series A Preferred Stock	——
Weighted Average Numberof Shares Dilutive Effect Of Series B Preferred Stock	——
EBIT	-$1.4M—
EBITDA	——
EBIT	-$1.4M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Evommune .

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's revenue?: Evommune (EVMN) generated $6.7M in revenue over the trailing twelve months.
Is Evommune profitable?: Evommune is not currently profitable: it reported a net loss of $6.0M over the trailing twelve months, a -90.1% net margin.
What are Evommune 's profit margins?: Gross margin is 53.7% and operating margin is -30.7%, with a -90.1% net margin.
What is Evommune 's earnings per share?: Evommune 's diluted EPS over the trailing twelve months is $-0.32.
Where does Evommune 's income statement data come from?: Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.